



an Open Access Journal by MDPI

Oncolytic Viruses and Combinatorial Immunotherapy for Cancer

Guest Editors:

Dr. Zong Sheng Guo

Department of Immunology,
Roswell Park Comprehensive
Cancer Center, Buffalo, NY, USA

Dr. Michael H. Lehmann

Institute for Infectious Diseases
and Zoonoses, Ludwig-
Maximilians-Universität
München, 85764
Oberschleißheim, Germany

Deadline for manuscript
submissions:

30 May 2024

Message from the Guest Editors

Dear Colleagues,

Oncolytic viruses (OVs) are developed as tools for novel cancer therapies. In recent years, investigators have started to realize that the indirect antitumor activity of viruses beyond direct oncolysis is a vital contributor to therapeutic efficacy. OV-induced antitumor immunity plays an important, sometimes essential, role in OV-mediated therapeutics for cancer.

OVs modulate the tumor microenvironment to favor antitumor immunity. Their ability to turn cold tumors immunologically hot is a unique property that makes OVs highly useful agents in combinatorial approaches for cancer immunotherapy.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-advancing field of biomedicine.

The submission of articles addressing (i) the mechanisms of action of OVs, (ii) genetic modifications of OVs for improving their efficacy and safety, (iii) the delivery of OVs, (iv) host responses to OVs and (v) studies with combinatorial approaches is strongly encouraged.

Dr. Zong Sheng Guo

Dr. Michael H. Lehmann

Guest Editors



mdpi.com/si/183928

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)